n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
Visiongain has published a new report: Genome Editing Technologies Market Report 2024-2034: Predictions through technology (CRISPR, TALEN, ZFN, Meganucleases, others), through applications (Genetic engineering (Cell line engineering, animal genetic engineering, plant genetic engineering, others). ), drug discovery and development, diagnostic applications), through end users (biotechnology corporations, pharmaceutical corporations, institutes of governmental and educational studies, others) AND major regional and national market studies PLUS primary corporation studies AND have an effect on and recovery of COVID-19 style studies.
The genome editing technologies market is estimated to be worth 6,360. 0 million US dollars in 2024 and is expected to grow at a CAGR of 17. 6% in the forecasted period 2024-2034.
The increasing incidence of genetic disorders and chronic diseases is driving the growth of the market
The genome editing and genetic treatment market is expanding and has been in a phase of strong expansion lately. This increase is due to the increasing appearance of genetic disorders and chronic diseases, which reinforce the need for effective therapies. Genome editing offers the long-term option. Short-term, even permanent, remedies for certain diseases, which particularly contributes to the expansion of the industry. Research is expanding to a variety of diseases, adding cancer, infectious diseases, and rare genetic diseases, as genetic treatment programs continue to expand. with advances in genetics and molecular biology. These advancements are attracting a lot of attention and funding, further accelerating the market’s progress.
In 2023, the incidence of chronic diseases remains high: 10 million new cases of cancer, 60 million cases of cardiovascular disease, 2. 5 million cases of lung cancer, 2. 3 million cases of breast cancer, and 0. 3 million cases of severe hemoglobin disorders. The increasing prevalence of chronic diseases such as cardiovascular diseases, neurodegenerative disorders, and orthopedic conditions is driving a very wide demand for genomic studies. This market is expected to grow in the coming years, largely due to the increasing number of cancer cases. patients, especially those with breast, bone, blood, and skin cancers. As highlighted by the World Health Organization (WHO), cancer remains one of the leading causes of death worldwide, highlighting the pressing need for advances in genomic studies and gene therapy. .
Download a https://www. visiongain. com/report/genome-editing-tech-market-2024/#download_sampe_div pattern report
How has COVID-19 affected the market for genome editing technologies?
COVID-19 has had a significant impact on the genome editing technologies market through the acceleration of studies and development. The pressing need for immediate diagnostic and cure responses during the pandemic has led to the widespread adoption of CRISPR-based diagnostic equipment. The teams have demonstrated the potential of genome editing technologies to ensure immediate and accurate detection of the virus, expanding its visibility and usefulness. This increased focus on CRISPR and other genome-editing technologies has spurred new inventions and applications, going beyond diagnostics to potential treatments and infectious disease preventative measures.
In addition, the pandemic has highlighted the importance of physically powerful and flexible biomedical study infrastructures, leading to increased investment and investment in genome editing technologies. Governments and the private sector have devoted really ample resources to genomic studies to better understand the virus and scale up effective countermeasures. This influx of investment has not only supported rapid COVID-19-like projects, but has also strengthened the overall capacity of the genome editing field. As a result, the genome editing technologies market is poised for sustained growth, driven through the progress made during the pandemic and the increased popularity of its transformative outlook in healthcare.
What will this report look like for you?
Visiongain’s 311-page report provides 127 tables and 182 charts/graphs. Our new study is suitable for anyone who wants in-depth business analyses of the genome editing technologies market, as well as detailed research of market segments. It will help you assess the global and regional market for genome editing technologies. Get monetary research of the overall market and other segments, adding the scale of operation, contract manufacturer size, stem mobile source, stem mobile type, and end user, and capture a superior market share. There are great opportunities in this rapidly developing market for genome editing technologies. Learn how to use existing and future opportunities in this market to generate profits in the near future. In addition, the report will help you improve your strategic decision-making, allowing you to outline expansion strategies, strengthen research from other market players, and maximize company productivity.
What are the market drivers?
Expanding Genomics Applications in Medicine, Agriculture, and Biotechnology Drives Industry Growth
Expanding genomics programs in precision medicine, agriculture, and biotechnology are generating a significant increase in demand for genome editing technologies. Tools such as CRISPR-Cas9, zinc finger nucleases, and TALEN allow for exact adjustments to the DNA sequence. simplifying genetic manipulation in various organisms. Continuous clinical advances in gene editing technologies are improving the profitability of the market. Notably, in January 2024, CRISPR Therapeutics obtained FDA approval for its CASGEVY product for the treatment of thalassemia, following a similar approval in December 2023. for sickle cell disease. The industry is also benefiting from favorable government regulations in artificial biology, increasing investment from governments and giant corporations, and increasing demand for engineered genes and mobile devices. Moreover, the progression and application of new gene editing techniques have especially contributed to the expansion of the market.
Genome editing technologies have the potential to revolutionize the treatment of genetic diseases by directly targeting and correcting mutations, creating demand in studies and clinical areas. Matrix CRISPR gene editing, especially in human-induced pluripotent stem cells (hiPSCs), holds great promise for stem cell research and the treatment of various diseases. Cell line engineering is very important in biotechnology, drug progression, and genetic cure because it allows for exact genetic modifications. Companies such as CRISPR Therapeutics and Editas Medicine are leading the progression of genome-editing cures through cutting-edge strategies, clinical trials, and partnerships, thus driving the expansion of the sector.
Increasing Demand for Genome Editing Technologies in Emerging Markets is Driving Market Expansion
Singapore, Russia, Brazil, India, China, Mexico, South Africa, South Korea, Indonesia, and Turkey are key emerging economies in the genome editing generation sector. In China, significant investments and advances in genome editing have positioned the country as a global country. Leader in studies and applications. Pioneering efforts in CRISPR-Cas9 generation through establishments such as BGI Genomics and Huada Genomics Institute have led to advances in human fitness and agriculture, addressing critical issues such as food security and sustainability.
The Chinese market presents a great opportunity for long-term expansion for life sciences research, driven by the growing healthcare demands of an aging population. According to the Office of National Statistics, spending on R
Get a detailed ToC https://www. visiongain. com/report/genome-editing-tech-market-2024/
Where are the market opportunities?
A strong pipeline of genome-editing products is expected to offer lucrative prospects for expansion.
The growing pipeline of genetic treatments in the gene editing industry offers prospects for significant advances in the treatment of genetic abgeneralities and other diseases. The genetic cure involves introducing healing genes into a patient’s cells using gene-editing equipment to correct or repair genetic mutations. general genetic function. In February 2023, GenScript, a China-based company, announced the expansion of its facilities in Singapore to decorate its high-end genetic synthesis services. This expansion has particularly improved the company’s genetic synthesis capabilities, allowing for cutting progression. Cutting-edge vaccines and remedies in the life sciences.
Advances in delivery technologies are expected to improve the protection and efficacy of gene therapies. Investment in complex delivery systems, such as lipid nanoparticles, exosomes, and viral vectors, will allow genetic treatment to target more challenging diseases and improve patient outcomes. In addition, gene combination treatment with other healing modalities, such as chemotherapy, immunotherapy, or targeted therapy, can treat complex disorders with multifactorial etiologies and improve the efficacy of cure. For example, the first human trial combining genetic treatment and immunotherapy, scheduled for September 2023, is expected to improve the survival rate of patients with malignant brain gliomas. These advancements are expected to drive product expansion during the forecast period.
Collaboration and alliances key actors
Collaboration between healthcare providers and medical device brands is achieving better outcomes for patients, which is driving market expansion. By partnering with healthcare providers, brands can better perceive clinical needs, refine device design, and ensure effective integration within healthcare systems. These collaborations also facilitate clinical trials, evidence generation, and reimbursement for genome editing technologies.
Recent developments underscore the importance of such partnerships. In April 2024, Agilent Technologies and the University of California, San Diego established the Agilent Center of Excellence in Cellular Intelligence. In March 2024, GenScript Biotech Corporation partnered with Roche and Lonza acquired primary biologics in the U. S. UU. de Roche. In addition, Sophia Genetics incorporated its DDM bioinformatics platform with Agilent Technologies’ new SureSelect Cancer Comprehensive Genomic Profiling Verification Kit in March 2023. In September 2023, Tecan and PacBio collaborated on genomics research, demonstrating the existing trend towards strategic partnerships. in industry.
Competitive Landscape
The market for genome editing technologies is highly fragmented, and many corporations are actively involved in it. Major players, including Thermo Fisher Scientific Inc. , GenScript, CRISPR Therapeutics, Revvity, Agilent Technologies Inc. , Merck KGaA, Sangamo Therapeutics Inc. , Lonza, Tecan Trading AG, Editas Medicine, and Precision Biosciences together accounted for a major percentage of the global market through 2023. Leading corporations, along with Thermo Fisher Scientific Inc. and CRISPR Therapeutics, are at the forefront of complex genome progression. editing technologies, such as CRISPR-Cas9 systems, engineered nucleases, and state-of-the-art delivery methods. Their commitment to innovation drives market evolution and sets new standards for technological advancements.
RECENT DEVELOPMENTS
In May 2024, Editas Medicine announced a two-year extension of its collaboration with Bristol Myers Squibb. This agreement allows the parties to continue their joint efforts in the research, progression and prospective commercialization of autologous and allogeneic alpha-beta T mobile treatments for the remedy against cancer and autoimmune diseases. In addition, the extension includes the possibility of extending the collaboration for up to two more years.
In April 2024, Cellectis introduced new TALEN editing processes found in HSPC correction and gene insertion.
In March 2024, Integrated DNA Technologies, a subsidiary of Danaher Corporation, will launch a new traditional vector integration to optimize gene synthesis.
In February 2024, Integrated DNA Technologies collaborated with Element Biosciences for Element’s AVITI system.
To learn about the contents of this document, please send an email to contactus@visiongain. com. Don’t miss a thing by staying informed – request our report now.
For more Visiongain research reports on the pharmaceutical sector, click on the links below:
Viral Vector and Plasmid DNA Manufacturing Market Report 2024-2034
Artificial Intelligence (AI) in Genomics Market Report 2023-2033
R Market Report
Do you have any traditional needs that we can meet? Do you want express data about an express country, geographic region, market segment, or company?Contact us today, we can talk about your wishes and see how we can: contactus@visiongain. com
About VisionGain
Visiongain is one of the fastest-growing, state-of-the-art independent commercial data providers in the market. The company publishes a large number of market research reports that it adds to its extensive portfolio each year. These reports will provide a detailed overview of studies of 18 industries around the world. The reports, which cover 10-year forecasts, are many pages long, with detailed market studies and valuable competitive intelligence data. Visiongain works in a variety of vertical markets with many synergies. They come with the automotive, aviation, chemical, cybersecurity, defense, energy, food and beverage, materials, packaging, pharmaceutical, and utilities sectors. Our customized, syndicated market research reports will deliver market data tailored to your business needs.
Contact
Visiongain Reports Limited Phone: (0) 20 7336 6100 Email: contactus@visiongain. com Web: www. visiongain. com